Daniel Molnar

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age

Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera et al. · Influenza and Other Respiratory Viruses · 2024 · 24 citations · Full text

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

Daniel Molnar, Elizabeth M. La, Frederik Verelst et al. · Infectious Diseases and Therapy · 2024 · 24 citations · Full text

The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis

Daisuke Kurai, Akiko Mizukami, Víctor Preckler et al. · Expert Review of Vaccines · 2024 · 11 citations · Full text